valu usd unless otherwis note
look end game ci esrx
view view sharehold bless merger welcom
expect news esrx although regul yet opin
deal view signific step toward close year-end
remain fan vertic consolid thesi believ ci/esrx
well posit evolv healthcar landscap
sharehold approv deal friday morn ci esrx
sharehold vote merger respect sharehold
meet esrx share outstand approv deal
vote meet vote cast favor
merger although drama earlier month activist
carl icahn public long ci short esrx plan
urg fellow ci sharehold vote merger howev
vote went larg expect icahn withdrew opposit two
spread compress reflect investor relief ci-esrx spread
stand littl chang prior day close spread
market close august day wsj report icahn
intent protest deal narrow steadili
manag reiter strateg rational expect
accret ep glenview capit manag long-tim
ci sharehold public support sharehold advisori firm
iss glass lewi advis sharehold vote deal deal
spread cvs-aet transact also indic
high degre investor confid deal close
wood yet path forward though
signific step note deal must still pass regulatori scrutini
close manag team indic expect
occur year-end believ chanc doj challeng
merger small especi given cvs/aet seem
clear path approv howev doj seek concess
secur deal approv suspect regul appeas
small divestitur overal think littl regulatori risk
see clear horizont overlap would give regul
paus unlik case cvs/aet regul report
analyz part benefit book may caus
divestitur aetna part book certain state
maintain outperform maintain outperform rate esrx
share rais pt reflect valu offer
current share price note upsid tie ci share
ci trade discount averag peer
price-to-earnings basi think vertic consolid ci/esrx cvs/
aet posit well evolv healthcar landscap
increas option beneficiari around care deliveri model
price prior trade day market close estimate unless otherwis note
express script provid pharmaci benefit manag
util client prescript benefit member pbm
network specialti mail pharmaci servic
clinic spend manag solut express script also
offer specialti distribut curascript busi
servic pharmaceut manufactur
announc termin relationship
express script contract end decemb
model contribut
stop start model benefit express
script would remov approxim one-third
estim ebitda express script calcul
valuat base busi without
expect multipl esrx share recov trade
line drug suppli chain peer group ex anthem
contribut forecast modest growth script volum
ebitda/rx stronger result either would drive better
expect ebitda growth
loss contract manag
govern regulatori scrutini pbm space
pbm industri competit price
bloomberg capit market estim upside/downside/target
price target esrx share base
current valu acquisit offer
acquisit cash ci share
share esrx
upsid scenario price base
price-to-earnings multipl appli ep estim still
exclud contribut ep estim
assum better expect core pbm ebitda growth
upsid scenario appli higher multipl
downsid scenario price base
price-to-earnings multipl appli ep estim ep
estim assum competit profit pressur limit
script volum growth appli lower multipl
discount multipl use drug suppli chain
compani reflect addit competit pressur
price target esrx share base current valu acquisit
offer acquisit cash ci share share
esrx price target support outperform rate
risk rate price target
risk profit competit pressur new entrant lower profit
pbm servic express script provid also downsid risk relat
lawsuit express script express script lose lawsuit
requir pay judgment would neg forecast
govern scrutini drug price drug suppli chain repres risk
pbm chang govern regul limit abil pbm creat formulari
retain percentag drug rebat could impact result express script
also risk express script need chang busi model gross net drug price
continu diverg consum expos increas gross cost drug
believ risk share deal fall could
neg impact esrx share believ risk long-term valu esrx
larg
express script provid pharmaci benefit manag pbm servic express
script manag prescript drug util client prescript benefit member pbm
servic includ drug formulari manag retail pharmaci network specialti mail
pharmaci servic clinic spend manag solut express script also
offer specialti distribut curascript busi servic pharmaceut
manufactur unit biosourc busi
rev depreci
revenu
revenu
 sg depreci
equiti jv
gaap net inc contin op
less ni attrib non-control interest
net incom attrib esrx
dilut share
basic share
